pharma · Kidney Dysfunction · Obesity
LianBio
Jian Li
LianBio clinical programs — 14 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- CN
- Founded
- 2019
- Employees
- 47
- Programs
- 28
- Drugs
- 40
- Patents
- 0
LianBio projects
14 ClinicalTrials.gov programs sponsored by LianBio.
LianBio has 14 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
626
Jian Li
Healthy Subjects (HS)
1 trial -
68Ga-FAPI-04
Jian Li
Fibrosis
1 trial -
APL-1202 and APL-1501 (Single ascending dose)
Jian Li
Bladder Cancer
1 trial -
Ad5-EBOV
Jian Li
Ebola Virus Disease
1 trial -
Daridorexant
Jian Li
Healthy Volunteer
1 trial -
GST-HG121 tablets
Jian Li
Pharmacokinetics
1 trial -
HRS-2329 Tablet
Jian Li
Advanced Solid Tumors Harboring RAS Mutations or Amplifications
1 trial -
HS-10345 84mg
Jian Li
Treatment Resistant Depressive Disorder
1 trial -
HS-10382(Part 1: Dose escalation)
Jian Li
CML, Chronic Phase
1 trial -
Nemonoxacin
Jian Li
Kidney Dysfunction
1 trial -
SHR-1501
Jian Li
Advanced Malignancies
1 trial -
SHR1459 tablet
Jian Li
B-cell Tumors
1 trial -
SHR2554 and Itraconazole
Jian Li
Healthy Adult Subjects
1 trial -
[14C] HRS-9190
Jian Li
Healthy Adult Male
1 trial
Frequently asked questions
How many clinical projects does LianBio have?
14 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.